Adjuvant RSV Vaccine in Older Adults

Author(s):

Carrie Koenigsfeld, PharmD, FAPhA

Carrie Koenigsfeld, PharmD, FAPhA, reviews the pivotal findings from the AReSVi-006 trial that supported the approval of the adjuvanted RSV vaccine, including its efficacy in preventing lower respiratory tract RSV, associated adverse events, and important study limitations that may have influenced the results.

Now Viewing

EP: 1.Adjuvant RSV Vaccine in Older Adults

EP: 2.Non-adjuvant RSV Vaccine in Older Adults

EP: 3.RSV Vaccine Efficacy in Pregnancy

EP: 4.Who Not to Vaccinate Against RSV

EP: 5.RSV Vaccine Administration Timing and Errors

EP: 6.Role of the Pharmacist in Vaccinating Against RSV

EP: 7.What is RSV?

EP: 8.Lasting Impacts of RSV

EP: 9.Limiting Transmission of RSV

EP: 10.Preparation of RSV Vaccines

EP: 11.Role of Pharmacists in Improving Vaccine Uptake

EP: 12.Pharmacists Enhancing RSV Care

While the follow-up data for the AReSVi-006 trial have not been published, what key results thus far have led to the approval of the adjuvanted vaccine?
1. Efficacy of preventing RSV-related lower respiratory tract disease
2. Adverse effects
3. Trial limitations